Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in primary nephropathy patients receiving glucocorticoids
ChiCTR2200058174Phase 4Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin in idiopathic membranous glomerulonephritis (IMG) (2 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Glycosylated hemoglobin, Fasting plasma glucose and 4 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2200058174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058174.